SCHEMBL3660641

SCHEMBL3660641

CC(C)c1ccc(CN2CC(Oc3ccc(-c4ccc(C(=O)O)cc4)cc3)C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
RXRA P19793 1/20 0.52
RXRB P28702 1/20 0.52
HRH3 Q9Y5N1 1/20 0.47
KCNH2 Q12809 2/20 0.46
HRH1 P35367 1/20 0.46
CCR3 P51677 1/20 0.46
MCHR1 Q99705 1/20 0.46
BCHE P06276 2/20 0.45
MAOB P27338 1/20 0.45
SRD5A2 P31213 1/20 0.45
S1PR5 Q9H228 7/20 0.45
S1PR1 P21453 6/20 0.45
SSTR5 P35346 1/20 0.44
PTPN1 P18031 1/20 0.43
RARB P10826 1/20 0.43
S1PR4 O95977 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522775 0.90 MEN1 (0.56) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL6527262 0.87 MEN1 (0.49) MEN1KMT2ARXRARXRBHRH3
SCHEMBL3659215 0.87 MEN1 (0.53) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL6523290 0.86 MEN1 (0.52) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL6521805 0.86 KMT2A (0.78) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL12788206 0.84 KMT2A (0.51) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL12788185 0.84 MEN1 (0.51) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL12788205 0.84 MEN1 (0.50) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL3654233 0.78 MEN1 (0.46) MEN1KMT2AHRH3KCNH2MCHR1
SCHEMBL12788189 0.78 MEN1 (0.44) MEN1KMT2AKCNH2MCHR1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
EP-2215077-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 EP disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists GPR119, GIPR, GPR39 MEN1 2395/4885KMT2A 3734/4885RXRA 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.